Key takeaway: The investor presentation for Gland Pharma Limited on Q1 FY27 financial results reported a 20% year-over-year increase in revenue from operations, reaching ₹18,003 million, with a gross profit margin of 65%. EBITDA increased by 34% to ₹4,930 million, resulting in an EBITDA margin of 27%. The presentation highlighted significant growth in both the CDMO and B2B segments, with CDMO revenue at ₹8,915 million and B2B revenue at ₹9,088 million. R&D expenses were noted at ₹772 million, representing 4% of consolidated revenue, focusing on complex product development. The company launched four new molecules in the USA and filed three ANDAs, with seven approvals in the quarter. The presentation also detailed strategic collaborations and a robust pipeline for future growth, including a partnership for Ready-to-Use infusion bags and a co-development agreement for sterile APIs.

Key takeaway: During the earnings call for Q4 FY '26, Gland Pharma Limited reported strong financial performance, with revenues of INR 17,428 million, reflecting a 22% year-on-year growth. The adjusted EBITDA for the quarter was INR 5,244 million, with margins of 30%. For the full year, revenues reached INR 64,307 million, a 14.5% increase, while adjusted EBITDA stood at INR 16,826 million, with margins of 26%. Management highlighted robust growth in the CDMO segment, new product launches, and improved performance from Cenexi as key drivers. The company launched 31 products in the U.S. during the year, contributing to strong revenue growth. Management expressed confidence in sustaining momentum through a pipeline of complex product launches and ongoing cost efficiency initiatives. The CDMO business represented 46% of total revenues, growing at 28%. Management set a goal of achieving a CAGR of 15% over the next four years.

Key takeaway: On May 15, 2026, Gland Pharma Limited submitted an investor presentation detailing its Q4 FY26 financial results. The presentation highlighted a 22% year-over-year increase in revenue from operations, reaching ₹17,428 million, and a total income growth of 26% to ₹18,543 million. Gross profit also rose by 23% to ₹11,515 million, maintaining a gross profit margin of 66%. Adjusted EBITDA increased by 51% to ₹5,244 million, with an adjusted EBITDA margin of 30%. The adjusted PAT saw a significant rise of 97% to ₹3,667 million, reflecting a margin of 21%. The company reported successful product launches and filings in the U.S. market, with a focus on complex injectables and new partnerships. Additionally, a final dividend of ₹20 per equity share was proposed, pending shareholder approval.

Key takeaway: During the earnings call for Q3 FY26, Gland Pharma Limited reported a strong quarter with a 22% year-on-year revenue growth to INR 16,954 million and a 25% increase in adjusted EBITDA to INR 4,490 million. Management highlighted broad-based growth across its businesses, including a notable turnaround at Cenexi, which achieved revenues of EUR 50 million. The company plans to invest approximately INR 2,000 crores over the next five years to expand its capabilities, particularly in ophthalmic and BFS lines. Management emphasized the importance of cost efficiency and margin sustainability, with R&D investments increasing to 5.4% of revenues. The company also discussed its pipeline of complex products and new CDMO partnerships, indicating a focus on long-term growth. Management expressed confidence in maintaining momentum and achieving sustained revenue growth.